Delgocitinib is under clinical development by Leo Pharma and currently in Phase II for Psoriasis. According to GlobalData, Phase II drugs for Psoriasis have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Delgocitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Delgocitinib overview

Delgocitinib (Corectim) acts as anti-allergic agent. It is formulated as ointment for topical application. Corectim is indicated for the treatment of atopic dermatitis.

Delgocitinib (JTE-052) is under development for the treatment of autoimmune/allergic diseases like chronic hand eczema, dry eye disease including Sjogren’s syndrome, mild to moderate inverse psoriasis and frontal fibrosing alopecia (FFA). The drug candidate is administered through topical, oral, cutaneous and ophthalmic routes. It acts by targeting pan Janus kinase (JAK ). It was also under development for discoid lupus erythematosus and alopecia areata.

Leo Pharma overview

Leo Pharma, a subsidiary of LEO Foundation, is a drug manufacturing company. It discovers, develops, manufactures, and commercializes medicines for skin diseases and thrombosis. Its product portfolio spans pharmaceuticals for the treatment of diseases such as eczema, psoriasis, skin infections, actinic keratosis, non-melanoma skin cancer, and thrombosis. The company also manufactures and markets products for the treatment of bacterial infections, coagulation, cardiovascular, antibiotics, nutritional disorders, osteoporosis, and renal problems. Leo Pharma markets its products worldwide. The company has a presence in Europe, the Middle East, Africa, Asia, the Americas, and Oceania. Leo Pharma is headquartered in Ballerup, Denmark.

For a complete picture of Delgocitinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.